In our former research, we demonstrated the pharmaceutical potential of GLP-1 in treating multiple diseases including diabetes [16], obesity [17], Alzheimer’s disease (AD) [18,19], and PD [19,20]. This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.